Peculiarities of the hormonal status on treatment of the patients with dysfunctional uterine bleeding (dub) during the premenopause with gestagens and combination of estrogen-gestagen preparations

E. G. Gumenyuk

Journal of obstetrics and women's diseases ›› 1998, Vol. 47 ›› Issue (3-4) : 57 -61.

PDF
Journal of obstetrics and women's diseases ›› 1998, Vol. 47 ›› Issue (3-4) : 57 -61. DOI: 10.17816/JOWD87458
Original study articles
research-article

Peculiarities of the hormonal status on treatment of the patients with dysfunctional uterine bleeding (dub) during the premenopause with gestagens and combination of estrogen-gestagen preparations

Author information +
History +
PDF

Abstract

166 patient (average age 44,82±0,40) with dysfunctional uterine bleeding (DUB) during premenopause were followed up. They were found to have hyperplasia of the endometrium of different forms. Hormonal therapy with different preparations (norcolut, orgametril, demulen, oxyprogesteron-capronat) was used. The patients with DUB during the premenopause may have different levels of gonadotropic and steroid hormones both on the background of DUB and during their treatment. These changes depend on a number of causes: age peculiarities, starting condition of hormonal homeostasis and mechanism of therapy action. We came to the conclusion that effectiveness of the treatment had not depended essentially on the patients' age, dynamics of peptid and steroid hormones level and type of the hormonal therapy to be used.

Keywords

hormonal status / uterine bleeding / premenopause / gestagens / estrogen-gestagens

Cite this article

Download citation ▾
E. G. Gumenyuk. Peculiarities of the hormonal status on treatment of the patients with dysfunctional uterine bleeding (dub) during the premenopause with gestagens and combination of estrogen-gestagen preparations. Journal of obstetrics and women's diseases, 1998, 47(3-4): 57-61 DOI:10.17816/JOWD87458

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Вихляева Е.М., Уварова Е.В., Самедова Н.Ч. К механизму лечебного эффекта норэтистерона при гиперпластических заболеваниях эндо- и миометрия у женщин репродуктивного возраста //Вопр. онкол. -1990. -Т. 36, №.6. -С. 683-689.

[2]

Гудкова М.А. Гормональная коррекция менструальной функции как метод терапии климактерического синдрома: Автореф. дис. ... канд. мед. наук. М., 1994. С. 24.

[3]

Корхов В.В. Клиникофармакологическая характеристика гормональных контрацептивов для энтерального применения // Фармакол. и токсикол. 1990. Т. 53, № 1. С. 77 - 80.

[4]

Макушева В.П. Контрацептивная эффективность и механизм действия комбиниаций этинилэстрадиола и норэтистерона ацетата //Фармакол. и токсикол. 1991. Т. 54, № З.С. 41 - 43.

[5]

Марченко Л.А. Эффективность лечения норколутом больных с дисфункциональными маточными кровотечениями в пременопаузе // Акуш. и гин., 1985. № 9. С. 20-23.

[6]

Пашкова В.С., Ерохин Ю.А. Влияние гормонального лечения гестагенами и эстроген-гестагенными гормонами на морфологию миоматозных узлов матки//Вопр. охраны мат. идет., 1991. Т. 36, № 11. С. 71.

[7]

Прилепская В.Н., Лобова Т.А. Гипоталамо-гипофизарно-тиреоидная система у больных с дисфункциональными маточными кровотечениями//Акуш. и гин., 1991. №9. С. 51-54.

[8]

Сметник В.П., Ткаченко Н.М., Глезер Г.А., Москаленко Н.П. Климактерический синдром. М.: Медицина, 1988. С. 288.

[9]

Хмельницкий О.К. Патоморфологическая диагностика гинекологических заболеваний (руководство). СПб.: Сотис, 1994. С. 144-184.

[10]

Friedman A.J., Thomas Р.Р. Does low-dose combination oral contraceptive use affect uterine size or menstrual flow in premenopausal women with leiomyomas?//Obstet. Gynecol., 1995. Vol. 85, №4. P. 631-635.

[11]

Gambrell R.D. Use of progestogen therapy//Am. J. Obstet. Gynecol. 1987. Vol. 156, №5. P. 1304-1313.

[12]

Kustan P. Ch. J., Kase N.G. Diagnosis and management of perimenopausal and postmenopausal bleeding //Obstet. Gynecol. Clin. N. Amer. 1987. Vol. 14, № 1. P. 169-189.

[13]

Marslew U., Riis B.J., Christiansen C. Bleeding patterns during continuous combined estrogen-progestagen therapy //Am. J. Obstet. Gynecol., 1991. Vol. 164, № 5, p. 1. P. 1163-1168.

[14]

Meng Y.X., Viratamasen P.X. Effect of norethisterone enanthate on endometrial bleeding and changes in coagulation function, ovarian hormones and endometrial histology in Thai women// Contraception. 1991. Vol. 44, № 1. P. 73-83.

[15]

Moyer D.L, de Lignieres B., Driguez R, PezJ.P. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence on bleeding pattern and secretory changes //Fertil. Steril., 1993. Vol. 59. № 5. P. 992-997.

[16]

Runnebaum B., Rabe T. New progestagens in oral contraceptives// Am. J. Obstet. Gynecol. 1987. Vol. 157, №4, p. 2. P. 1059- 1063.

[17]

Saarikoski S., Yliskoski M., Penttila I. Sequential use of norethisterone and natural progesterone in premenopausal bleeding disorders//Matiritas. 1990. - Vol. 12. P. 89-97.

[18]

Salvat J., Jolies C. Progesterone, progestatifs dans le syndrome premenopausal le perimenopause et la menopause //Schweiz-Rundsch-Med- Prax., 1995. Vol. 84, № 3. P. 70-75.

[19]

Schlesselman J.J. Oral contraceptives and neoplasia of the uterine corpus//Contraception., 1991. Vol. 43, №6. P. 557-581.

[20]

Song J. M., Fraser I. S. Effects of progestogens on human endometrium // Obstet. Gynecol. Surv., 1995. Vol. 50, № 5. - P. 385-394.

[21]

Whitehead M.I., Fraser D. The effects of estrogen and progestagens on the endometrium. Modern approach to treatment //Obstet. Gynecol. Clin. N. Amer. 1987. Vol. 14. №1. P. 299-320.

[22]

Whitehead M.I., Hillard B.M., Crooke D. The role and use of progestogens// Obstet. Gynecol. 1990. Vol. 75, №4 (suppl.). P. 598-768.

RIGHTS & PERMISSIONS

Eсо-Vector

AI Summary AI Mindmap
PDF

134

Accesses

0

Citation

Detail

Sections
Recommended

AI思维导图

/